• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.

作者信息

Iland Harry J, Russell Nigel, Dillon Richard, Schuh Andre C, Tedjaseputra Aditya, Wei Andrew, Khwaja Asim, Knapper Steven, Lane Steven W, Reynolds John, McMullin Mary Frances, Martin Annalise, Tan Peter, Taussig David C, Wong Anny, Taper John, Fraga Christina, Kelly Richard, Tawana Kiran, Mehta Priyanka, Mina Alain, Altman Jessica K, Mølle Ingolf, Tauro Sudhir, Tholouli Eleni

机构信息

Institute of Haematology, Royal Prince Alfred Hospital and University of Sydney, Camperdown, Australia.

Department of Haematology, Guy's and St Thomas' Hospital, London, United Kingdom.

出版信息

Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126.

DOI:10.1182/bloodadvances.2022007126
PMID:36075018
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10250923/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc8/10250923/717f0c0ad9b6/BLOODA_ADV-2022-007126-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc8/10250923/717f0c0ad9b6/BLOODA_ADV-2022-007126-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1bc8/10250923/717f0c0ad9b6/BLOODA_ADV-2022-007126-gr1.jpg

相似文献

1
Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation.初诊时急性早幼粒细胞白血病伴极度白细胞增多患者的特征及预后
Blood Adv. 2023 Jun 13;7(11):2580-2585. doi: 10.1182/bloodadvances.2022007126.
2
Hypoxemia During Extreme Hyperleukocytosis: How Spurious?
Respir Care. 2016 Jan;61(1):8-14. doi: 10.4187/respcare.04196. Epub 2015 Sep 29.
3
[Retinoic acid in treating acute promyelocytic leukemia with hyperleukocytosis and its therapeutic strategy].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Apr;16(2):439-41.
4
CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.CD2+急性早幼粒细胞白血病与白细胞增多、形态变异及预后较差相关。
Clin Lab Haematol. 2005 Oct;27(5):307-11. doi: 10.1111/j.1365-2257.2005.00715.x.
5
Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia.进行性高白细胞血症是急性早幼粒细胞白血病分化综合征、早期死亡和后续复发的一个相关预测指标。
Sci Rep. 2019 Aug 15;9(1):11935. doi: 10.1038/s41598-019-47937-4.
6
Acute Budd-Chiari syndrome as an initial presentation of acute promyelocytic leukemia.
J Cancer Res Ther. 2010 Oct-Dec;6(4):567-9. doi: 10.4103/0973-1482.77077.
7
Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis.急性髓系白血病合并高白细胞血症患儿在未进行白细胞单采术的情况下接受快速化疗后的早期轻微发病率。
J Formos Med Assoc. 2014 Nov;113(11):833-8. doi: 10.1016/j.jfma.2014.01.006. Epub 2014 Feb 15.
8
[Hyperleukocytosis in a variant form of acute promyelocytic leukemia].
Rinsho Ketsueki. 1988 Sep;29(9):1437-41.
9
The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.口服或静脉注射砷剂作为急性早幼粒细胞白血病一线治疗时白细胞的动力学及白细胞增多的预测因素
Leuk Res. 2017 Oct;61:84-88. doi: 10.1016/j.leukres.2017.09.006. Epub 2017 Sep 14.
10
Hyperleukocytosis in infant acute leukemia: a role for manual exchange transfusion for leukoreduction.婴儿急性白血病中的高白细胞血症：手工换血在白细胞去除中的作用。
Transfusion. 2018 May;58(5):1149-1156. doi: 10.1111/trf.14512. Epub 2018 Feb 4.

引用本文的文献

1
Emergencies in Hematology: Why, When and How I Treat?血液学急症：为何、何时以及如何进行治疗？
J Clin Med. 2024 Dec 12;13(24):7572. doi: 10.3390/jcm13247572.
2
Standard dose anthracycline plus all-trans retinoic acid and arsenic trioxide as induction chemotherapy significantly reduces early death and relapse for high-risk acute promyelocytic leukemia: a single-center real-world analysis.标准剂量蒽环类药物联合全反式维甲酸和三氧化二砷作为诱导化疗可显著降低高危急性早幼粒细胞白血病的早期死亡和复发率：一项单中心真实世界分析
Ther Adv Hematol. 2024 Nov 19;15:20406207241299699. doi: 10.1177/20406207241299699. eCollection 2024.
3
Complete elimination of hyperleukocytosis risk in AML through early high-quality disease remission.

本文引用的文献

1
Arsenic trioxide replacing or reducing chemotherapy in consolidation therapy for acute promyelocytic leukemia (APL2012 trial).三氧化二砷替代或减少急性早幼粒细胞白血病（APL2012 试验）巩固治疗中的化疗。
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6). doi: 10.1073/pnas.2020382118.
2
Curative strategies in APL.APL 的治疗策略。
Semin Hematol. 2019 Apr;56(2):131-138. doi: 10.1053/j.seminhematol.2018.07.004. Epub 2018 Aug 23.
3
Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.
通过早期实现高质量的疾病缓解，完全消除急性髓系白血病中高白细胞血症的风险。
Front Oncol. 2024 Jun 13;14:1412583. doi: 10.3389/fonc.2024.1412583. eCollection 2024.
急性早幼粒细胞白血病的治疗：欧洲白血病网专家小组的最新建议。
Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25.
4
Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab.全反式维甲酸、三氧化二砷和吉妥单抗治疗急性早幼粒细胞白血病的长期疗效
Blood. 2017 Mar 9;129(10):1275-1283. doi: 10.1182/blood-2016-09-736686. Epub 2016 Dec 21.
5
Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.澳大利亚和新西兰白血病与淋巴瘤组（ALLG）APML4研究中三氧化二砷用于急性早幼粒细胞白血病诱导缓解和巩固治疗：一项非随机2期试验
Lancet Haematol. 2015 Sep;2(9):e357-66. doi: 10.1016/S2352-3026(15)00115-5. Epub 2015 Aug 20.
6
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.三氧化二砷和全反式维甲酸治疗所有风险组急性早幼粒细胞白血病（AML17）：一项随机、对照、3 期临床试验的结果。
Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.
7
Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study.急性早幼粒细胞白血病的特点是发病率稳定且生存率提高，但仅限于在白血病转诊中心接受治疗的患者：一项全加拿大的流行病学研究。
Br J Haematol. 2014 Sep;166(5):660-6. doi: 10.1111/bjh.12931. Epub 2014 Apr 30.
8
Arsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.三氧化二砷在急性早幼粒细胞白血病一线治疗中（C9710）：FLT3突变和复杂核型的预后意义
Leuk Lymphoma. 2014 Jul;55(7):1523-32. doi: 10.3109/10428194.2013.842985. Epub 2014 Feb 4.
9
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.全反式维甲酸和三氧化二砷联合治疗急性早幼粒细胞白血病。
N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874.
10
Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17).伴有 t(15;17)的初发急性早幼粒细胞白血病患者中额外染色体异常的预后意义。
Med Oncol. 2012 Sep;29(3):2095-101. doi: 10.1007/s12032-012-0251-7. Epub 2012 May 22.